PNPLA3 and metabolic dysfunction-associated steatotic liver disease: As shown in Figure 2, PNPLA3 inhibition was associated with a reduced risk of NAFLD (OR: 0.08, 95% CI: 0.05 to 0.14, p=1.157 × 10−20) and fibrosis and cirrhosis of the liver (OR: 0.17, 95% CI: 0.10 to 0.30, p=2.174 × 10−9) (Figure s1).